Roche highlights Tecentriq results in triple negative breast cancer

ZURICH (Reuters) - Swiss drugmaker Roche said on Monday that a trial showed its immunotherapy Tecentriq plus the chemotherapy Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.

from Reuters: Health News https://ift.tt/2u3fwjV